EU Reforms Offer Mixed Blessings For Generics And Biosimilars
Changes To Regulatory Data Protection And Faster, Simpler Authorization Procedures
Executive Summary
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures that will affect the generics and biosimilars industry – including changes to regulatory data protection periods, simplified marketing authorization procedures, and moves towards greater digitalization.
You may also be interested in...
European Industry Voices Concern As Products Vanish From Market
A fresh report has offered stark new data on the extent to which generics are disappearing from the European market. Industry association Medicines for Europe has pointed to the risks of supply consolidation, urging both national- and EU-level action.
EU Pharma Reform Proposes Cuts In Regulatory Protections & Faster Drug Approval Times
Proposals for the overhaul of the EU pharmaceutical legislation will make medicines more widely available, accessible and affordable while supporting innovation and boosting the “competitiveness and attractiveness” of Europe’s pharma industry, the European Commission claims. The research-based industry thinks otherwise, saying cuts in regulatory protections will undermine R&D.
EU Pharma Strategy Offers Window For Regulatory Optimization
Attendees to Medicines for Europe’s Regulatory Affairs and Pharmacovigilance virtual conference heard that a window of opportunity to optimize the region’s regulatory landscape is now “wide open” with the advent of the new EU Pharmaceutical Strategy.